

**Date:** January 07, 2026

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

**Sub.: Outcome of Board Meeting of the Company – Disclosure under Regulation 30, 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and in furtherance to our intimation dated January 03, 2026, we would like to inform you that the Board of Directors of the Company (“**Board**”) at its meeting held today i.e., Wednesday, January 07, 2026, has inter-alia considered and approved the following matters:

**1. Issuance of convertible equity warrants by way of preferential issue (“Preferential Issue”)**

Subject to the approval of shareholders of the Company and such other regulatory or statutory authorities, as may be required, the Board has approved to create, offer, issue and allot by way of a Preferential Issue of up to **11,70,000** (Eleven Lakh Seventy Thousand) fully convertible equity warrants (“**Warrants**”), each carrying a right exercisable by the warrant holder to subscribe to one (1) equity share of the face value of ₹10/- (Rupees Ten only) each against each Warrant at an issue price of **₹812/-** (Rupees Eight Hundred and Twelve Only) per Warrant (including a premium of ₹802/- (Rupees Eight Hundred and Two Only), as determined in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”) to persons belonging to Promoter and Promoter Group and as mentioned in Annexure A on a private placement basis aggregating to total consideration of **₹ 95,00,40,000/-** (Rupees Ninety-Five Crores Forty Thousand Only), representing 2.48% of the fully diluted paid-up capital of the Company, which may be exercised in one or more tranches during the period commencing from the date of allotment of the warrants until expiry of 18 (Eighteen) months from the date of allotment of the warrants and on such terms and condition as may be determined by the Board.

The information in connection with the issuance of securities pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure A**.

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

2. The Board has fixed the Relevant Date, in terms of provisions of the SEBI ICDR Regulations for determining the floor price for the preferential issue i.e., **Thursday, January 01, 2026.**
3. The Board has approved the notice of the Extra-ordinary General Meeting of the Company ("**EGM**") to be held on Saturday, January 31, 2026 at 12:30 P.M. (IST) through Video Conferencing (VC)/ Other Audio Video Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India, for obtaining the approval of the shareholders of the Company for the matter as discussed above and such other matters as necessary.
4. The Board has fixed January 02, 2026, as the cut-off date for the purpose of the dispatch of the EGM notice electronically, along with the details of e-voting to the shareholders of the Company.
5. The Board has appointed M/s. Mukesh H. Shah & Co., Practicing Company Secretaries (CP No. 2213 /Membership No.: FCS 5827), Ahmedabad as the Scrutinizer to scrutinize the remote e-voting and e-voting during the forthcoming EGM in a fair and transparent manner.

Kindly note that the meeting of Board of Directors of the Company commenced at 03:00 P.M. (IST) and concluded at 03:35 P.M. (IST).

The Notice of the EGM and other relevant documents shall be submitted in due course.

This intimation and aforesaid information are also being uploaded on the Company's website at [www.senorespharma.com](http://www.senorespharma.com).

You are requested to take the same on record.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

Enclosures: As above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

**Annexure A**
**DISCLOSURE PURSUANT TO THE SEBI LODR REGULATIONS READ WITH THE SEBI MASTER CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/0155 DATED NOVEMBER 11, 2024.**

Sr. No.	Particulars	Disclosure														
1.	Type of securities proposed to be issued	Fully convertible equity warrants (“Warrants”) each carrying a right exercisable by the warrant holder to subscribe to one (1) equity share of face value of ₹10/- each upon the exercise of the option attached to each such Warrant which may be exercised in one or more tranches during the period commencing from the date of allotment of the warrants until expiry of 18 (Eighteen) months from the date of allotment of the warrants. Warrants will be unlisted.														
2.	Type of issuance	Preferential issue of Warrants in accordance with the provisions of the Companies Act, 2013 and the rules framed thereunder and provisions of Chapter V of the SEBI ICDR Regulations and other applicable laws.														
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	<p>Up to <b>11,70,000 (Eleven Lakh Seventy Thousand) Warrants</b> each carrying a right exercisable by the warrant holder to subscribe to one (1) equity share of the face value of ₹ 10/- (Rupees Ten only) each against each Warrant at an exercise price of ₹ <b>812/- (Rupees Eight Hundred and Twelve Only)</b> per Warrant aggregating to ₹ <b>95,00,40,000/- (Rupees Ninety-Five Crores Forty Thousand Only)</b>.</p> <p>The Preferential Issue will be undertaken for cash consideration. For Warrants, an amount equivalent to at least 25% (Twenty-Five per cent) of the exercise price shall be payable to the Company at the time of allotment of the Warrants, and the balance of the exercise price shall be payable to the Company upon exercise of the option attached to the relevant Warrants for conversion to the equity shares.</p>														
4.	Details to be furnished in case of preferential issue															
	a. Name of the investor(s)	1. Swapnil Jatin Shah 2. Renosen Pharmaceuticals Private Limited 3. Ashokbhai Vijaysinh Barot 4. Sangeeta Mukur Barot 5. Viraj Ashokkumar Barot														
	b. Post allotment of securities -outcome of the subscription, issue price /allotted price (in case of convertibles), number	<p><b>Outcome of allotment:</b></p> <table><tr><th rowspan="2">Investor</th><th colspan="2">Pre-Issue shareholding</th><th colspan="2">Post-issue shareholding*</th></tr><tr><th>No.</th><th>%</th><th>No.</th><th>%</th></tr><tr><td>Swapnil Jatin Shah</td><td>3553531</td><td>7.7161</td><td>3750531</td><td>7.9421</td></tr></table>	Investor	Pre-Issue shareholding		Post-issue shareholding*		No.	%	No.	%	Swapnil Jatin Shah	3553531	7.7161	3750531	7.9421
Investor	Pre-Issue shareholding			Post-issue shareholding*												
	No.	%	No.	%												
Swapnil Jatin Shah	3553531	7.7161	3750531	7.9421												

**Senores Pharmaceuticals Limited**

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

Sr. No.	Particulars	Disclosure				
	of investors	Renosen Pharmaceuticals Private Limited	2718719	5.9034	3457719	7.3220
		Ashokbhai Vijaysinh Barot	3444869	7.4801	3567869	7.5553
		Sangeeta Mukur Barot	1042955	2.2647	1104455	2.3388
		Viraj Ashokkumar Barot	0	0.0000	49500	0.1048
		<b>Total</b>	<b>10760074</b>	<b>23.3642</b>	<b>11930074</b>	<b>25.2630</b>
<p><i>*Assuming full conversion of warrants</i></p> <p><b>Issue Price:</b></p> <p>Up to <b>11,70,000 (Eleven Lakh Seventy Thousand) Warrants</b> each carrying a right exercisable by the warrant holder to subscribe to one (1) equity share of the face value of ₹10/- (Rupees Ten only) each against each Warrant at an exercise price of <b>₹812/- (Rupees Eight Hundred and Twelve Only)</b> per Warrant aggregating to <b>₹ 95,00,40,000/- (Rupees Ninety-Five Crores Forty Thousand Only)</b>.</p> <p>The Preferential Issue will be undertaken for cash consideration. For Warrants, an amount equivalent to at least 25% (Twenty-Five per cent) of the exercise price shall be payable to the Company at the time of allotment of the Warrants, and the balance of the exercise price shall be payable to the Company upon exercise of the option attached to the relevant Warrants for conversion to the equity shares.</p> <p><b>Number of Investors:</b> There are <b>5(five)</b> investors to whom Warrants are being issued.</p>						
	c. In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	<p>Each Warrant is exercisable into one (1) equity share having a face value of ₹10/- (Rupees Ten only) each. The tenor of the Warrants is 18 months from the date of their allotment. The Warrants shall be convertible in one or more tranches.</p> <p>In case the Warrant holder does not apply for the conversion of the outstanding Warrants into Equity Shares of the Company within 18 (Eighteen) months from the date of allotment of the said Warrants, then the amount paid on each of the said outstanding Warrants shall be forfeited and all the rights attached to the said Warrants shall lapse automatically.</p>				

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

Sr. No.	Particulars	Disclosure
5.	Any cancellation or termination of proposal for issuance of securities Including reasons thereof	Not applicable

Committed to  
Global Wellness!

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263